Physician profile
Negin Behazin
NPI 1497076301
$3,166.45
in general payments reported to CMS, 2019-2025
25 companies · $331 in 2025
The $331 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2021: $239 · 2022: $566 · 2023: $952 · 2024: $587 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,870.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $635.83 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $516.63 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $252.67 | 2019-2024 | Xifaxan |
| Acadia Pharmaceuticals INC | $246.12 | 2023 | Nuplazid |
| Abbvie INC. | $163.88 | 2021-2023 | Vraylar, Ubrelvy, Qulipta |
| Idorsia Pharmaceuticals US INC | $156.76 | 2023 | Quviviq |
| Grifols USA, LLC | $147.33 | 2019-2023 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals LP | $130.25 | 2023-2025 | Airsupra, Farxiga |
| Teva Pharmaceuticals USA, INC. | $120.85 | 2024 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $117.42 | 2022 | |
| Merck Sharp & Dohme LLC | $113.67 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Exact Sciences Corporation | $84.12 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $82.42 | 2023-2025 | Wegovy, Ozempic |
| Gilead Sciences, INC. | $53.12 | 2022-2023 | |
| Pfizer INC. | $45.76 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $43.33 | 2019 | |
| Amgen INC. | $42.33 | 2019-2025 | Repatha |
| Glaxosmithkline, LLC. | $40.85 | 2022-2023 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $35.85 | 2019 | |
| Allergan, INC. | $34.89 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $25.94 | 2024 | Eliquis |
| Vanda Pharmaceuticals INC. | $22.92 | 2022 | |
| Astellas Pharma US INC | $20.05 | 2019 | |
| Electromed, INC. | $18.83 | 2025 | Smartvest |
| Endogastric Solutions, INC | $14.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Negin Behazin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.